Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Welmoed Kirsten van Deen, MD

    TitleAssistant Professor of Research Medicine
    SchoolKeck School of Medicine of USC
    DepartmentMedicine
    AddressGNH 1937 Hospital Place
    Off Campus
    Los Angeles California 90031

       Overview 
       Overview
      Dr. van Deen's major areas of research interest are value-based healthcare implementation and outcome and utilization measurement. She is currently a member of the International Consortium for Health Outcomes Measurement (ICHOM) IBD Standard Set Working Group.

      Dr. van Deen earned her medical degree from Leiden University Medical Center. She then returned to complete her PhD in Medicine a few years later.


       Biography 
       Awards and Honors
      Leiden University, The Netherlands2011LUSTRA Travel Scholarship
      American Gastroenterological Association2015Digestive Disease Week Poster of Distinction Award

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. van Deen WK, Spiro A, Burak Ozbay A, Skup M, Centeno A, Duran NE, Lacey PN, Jatulis D, Esrailian E, van Oijen MG, Hommes DW. The impact of value-based healthcare for inflammatory bowel diseases on healthcare utilization: a pilot study. Eur J Gastroenterol Hepatol. 2016 Dec 06..
        View in: PubMed
      2. van Deen WK, Nguyen D, Duran NE, Kane E, van Oijen MG, Hommes DW. Value redefined for inflammatory bowel disease patients: a choice-based conjoint analysis of patients' preferences. Qual Life Res. 2017 Feb; 26(2):455-465..
        View in: PubMed
      3. Van Deen WK, van der Meulen-de Jong AE, Parekh NK, Kane E, Zand A, DiNicola CA, Hall L, Inserra EK, Choi JM, Ha CY, Esrailian E, van Oijen MG, Hommes DW. Development and Validation of an Inflammatory Bowel Diseases Monitoring Index for Use With Mobile Health Technologies. Clin Gastroenterol Hepatol. 2016 Dec; 14(12):1742-1750.e7..
        View in: PubMed
      4. Oikonomopoulos A, van Deen WK, Manansala AR, Lacey PN, Tomakili TA, Ziman A, Hommes DW. Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media. Sci Rep. 2015; 5:16570.; PMCID: PMC4643287.
        View in: PubMed
        View in: PubMed Central
      5. Zand A, van Deen WK, Inserra EK, Hall L, Kane E, Centeno A, Choi JM, Ha CY, Esrailian E, D'Haens GR, Hommes DW. Presenteeism in Inflammatory Bowel Diseases: A Hidden Problem with Significant Economic Impact. Inflamm Bowel Dis. 2015 Jul; 21(7):1623-30..
        View in: PubMed
      6. Polytarchou C, Hommes DW, Palumbo T, Hatziapostolou M, Koutsioumpa M, Koukos G, van der Meulen-de Jong AE, Oikonomopoulos A, van Deen WK, Vorvis C, Serebrennikova OB, Birli E, Choi J, Chang L, Anton PA, Tsichlis PN, Pothoulakis C, Verspaget HW, Iliopoulos D. MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice. Gastroenterology. 2015 Oct; 149(4):981-992.e11.; NIHMSID: NIHMS698191 [Available on 10/01/16].
        View in: PubMed
      7. van Deen WK, Esrailian E, Hommes DW. Value-based health care for inflammatory bowel diseases. J Crohns Colitis. 2015 May; 9(5):421-7..
        View in: PubMed
      8. van Deen WK, van Oijen MG, Myers KD, Centeno A, Howard W, Choi JM, Roth BE, McLaughlin EM, Hollander D, Wong-Swanson B, Sack J, Ong MK, Ha CY, Esrailian E, Hommes DW. A nationwide 2010-2012 analysis of U.S. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis. 2014 Oct; 20(10):1747-53..
        View in: PubMed
      9. Oikonomopoulos A, van Deen WK, Hommes DW. Anti-TNF antibodies in inflammatory bowel disease: do we finally know how it works? Curr Drug Targets. 2013 Nov; 14(12):1421-32..
        View in: PubMed
      10. van Deen WK, Hommes DW. IBD: Antibodies to anti-TNF therapy--consequences for IBD management. Nat Rev Gastroenterol Hepatol. 2013 Aug; 10(8):446-8..
        View in: PubMed
      11. van Deen WK, Oikonomopoulos A, Hommes DW. Stem cell therapy in inflammatory bowel disease: which, when and how? Curr Opin Gastroenterol. 2013 Jul; 29(4):384-90..
        View in: PubMed
      12. van Deen WK, Hommes DW. Mucosal schwann cell hamartoma in ulcerative colitis: diagnosis and clinical relevance. Gastroenterol Hepatol (N Y). 2013 Mar; 9(3):185-6.; PMCID: PMC3745210.
        View in: PubMed
        View in: PubMed Central
      13. Molendijk I, Duijvestein M, van der Meulen-de Jong AE, van Deen WK, Swets M, Hommes DW, Verspaget HW. Immunomodulatory effects of mesenchymal stromal cells in Crohn's disease. J Allergy (Cairo). 2012; 2012:187408.; PMCID: PMC3459229.
        View in: PubMed
        View in: PubMed Central
      Back to TOP